Elevance Health, Inc. (ELV) Stock Price & How to Invest

Last updated November 2026

Short answer

ELV is Elevance Health, one of the largest US health insurers (the former Anthem), reachable through any standard brokerage. It trades as a value-priced healthcare giant: enormous, cash-generative, and highly regulated, with the debate centered on whether rising medical costs (especially in Medicaid) squeeze margins faster than premium repricing can catch up. As of November 20, 2026 the shares closed near $405, up about 14% year to date and about 29% over one year, for a market value of roughly $87 billion, after a third-quarter beat on October 21 and a sector-wide selloff on November 18 over a federal Medicare Advantage proposal.

ELV stock price

As of 2026-11-20, Elevance Health, Inc. (ELV) last closed at $394.48, up 22.6% over the past year. Over the past 52 weeks it has traded between $280.74 and $446.28.

ELV last close
$394.48
1 day
+1.11%
1 month
-9.13%
1 year
+22.61%
52-week range
$280.74 to $446.28
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Elevance Health, Inc.'s investor relations page. Walnut is informational, not investment advice.

ELV key stats

At $394.48 on November 20, 2026, Elevance Health, Inc. (ELV) has a market cap of $85.2B, a P/E of 16.7 on trailing earnings (13.0 on forward earnings) and a dividend yield of 1.74%. It next reports earnings around January 28, 2027 (estimated).

Market cap
$85.2B
P/E (trailing)
16.7
P/E (forward)
13.0
EPS (trailing 12 months)
$23.55
Price to book
1.9
Dividend yield
1.74%
Beta
0.63
Next earnings
around January 28, 2027 (estimated)

Market cap, P/E and yield are measured at the $394.48 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Elevance Health, Inc. (ELV)?

The last two weeks for Elevance Health, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ELV closed at $394.48 on November 20, 2026, down 8.2% over the past five trading days (from $429.69).
  • Elevance Health, Inc. next reports quarterly results around January 28, 2027 (estimated).
  • On November 10, 2026, Elevance Health, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 18, 2026, Argus Research started coverage at Buy, target $510.00.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Elevance Health, Inc. (ELV) do?

Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. Its Health Benefits segment sells commercial, Medicare Advantage, Medicaid, and ACA marketplace plans, operating Blue Cross Blue Shield plans across 14 states, while its fast-growing Carelon segment houses pharmacy benefits (CarelonRx) and risk-based care services. Operating revenue reached roughly $197.6 billion in 2025, with Carelon revenue climbing about 33 percent on CarelonRx growth and the CareBridge acquisition.

The investment picture is that of a mature, defensive cash machine trading at a modest earnings multiple that mostly captures market worry about medical cost inflation rather than doubt about the franchise. Management raised full-year 2026 adjusted EPS guidance to at least roughly $26.75 after a Q1 2026 beat, but flagged a higher benefit expense ratio driven by Medicaid cost trend. Q2 2026 then came in ahead of expectations as well: revenue of about $49.8 billion, GAAP net income of about $1.46 billion and adjusted EPS of $7.45 against a consensus near $6.21. Q3 2026, reported October 21, was a bigger beat still: operating revenue of about $50.4 billion, up 0.7%, and adjusted EPS of $6.99 against a consensus near $4.69, with the benefit expense ratio improving 70 basis points year over year to 90.6%. Medical membership slipped about 1.1% to roughly 44.9 million, and the Health Benefits segment's operating gain fell about 27.5%, so the beat leaned on Carelon and cost management. Management raised 2026 guidance to adjusted EPS of at least $29, lifted its underlying baseline to at least $26.75, and said it expects at least 12% adjusted EPS growth in 2027 from that baseline. The stock closed at a 52-week high of about $446 on November 16, then fell 7.6% on November 18 when the whole managed care group sold off on a federal proposal that could let regulators recover Medicare Advantage overpayments dating back to 2018 (Humana fell 13% and UnitedHealth about 10% that day). As of November 20, 2026 ELV closed near $405, up about 14% year to date and about 29% over one year. Investors weigh Elevance's scale, diversification into services, and shareholder returns against a regulated, thin-margin insurance model where a few points of medical loss ratio move earnings materially.

What's driving Elevance Health, Inc. (ELV)?

1. Carelon services and pharmacy expansion

Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. This shifts Elevance's mix toward higher-growth, capital-lighter services revenue that is less exposed to pure insurance underwriting swings. Management frames Carelon as a core margin and growth engine alongside traditional insurance.

2. Government programs repricing

Medicare Advantage membership growth and Medicaid rate updates are central to the 2026 story. Elevance has been pressing state partners for Medicaid rates that better reflect the acuity of members retained after post-pandemic redeterminations. If premium yields catch up to medical cost trend, margins in government business can normalize over the coming year. On the Q3 call management said its Medicare Advantage plans were on track for an operating margin of at least 2% in 2026, below the 3% to 5% long-term target, and a November 2026 federal proposal on recovering past Medicare Advantage overpayments adds a new policy question to that line.

3. Capital return and low valuation

Elevance generates substantial cash, funding dividends of about $6.88 per share a year (a yield near 1.8%) and buybacks, with trailing free cash flow of about $8.0 billion. After the November pullback the stock trades at about 17x trailing GAAP earnings and about 13.4x forward estimates, below the broad market and still above the 11-12x multiple seen in April 2026. Continued EPS growth combined with share repurchases is a key part of how the stock is positioned; management targets at least 12% adjusted EPS growth in 2027 from a baseline of at least $26.75, and consensus looks for 2027 EPS of roughly $30.29.

4. Diversification across the insurance book

A spread across commercial (employer and individual), Medicare, Medicaid, and ACA marketplace plans gives Elevance multiple demand pools. Softness in one line, such as Medicaid cost pressure, can be partly offset by strength elsewhere, including a noted shift toward bronze-tier ACA plans. This breadth is the buffer against any single program's cost shock.

What are the risks to Elevance Health, Inc. (ELV)?

The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and 90.6 percent in the seasonally heavier Q3, and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple. Policy risk showed up directly on November 18, 2026, when a federal proposal to recover Medicare Advantage overpayments dating back to 2018 knocked ELV down 7.6% in a day, and medical membership is shrinking slightly (about 1.1% lower year over year in Q3). Near term, consensus expects Q4 2026 EPS of about $2.07, roughly 38% below a year earlier, ahead of a report expected around January 28, 2027.

What is the Elevance Health, Inc. (ELV) forecast?

21 analysts publish price targets on ELV, averaging $482.38 as of November 2026, or +22.3% against the $394.48 share price on November 20, 2026. The published targets run from $406.00 to $523.00, a narrow spread, and the ratings split 16 buy, 6 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ELV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ELV a buy or a sell?

We give no verdict on Elevance Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Carelon services and pharmacy expansion. Carelon, which includes CarelonRx and risk-based care services, grew operating revenue about 33 percent in 2025 to roughly $71.7 billion, aided by the CareBridge acquisition. The most optimistic published target, $523.00, assumes this works close to its best case.

The case against. The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and 90.6 percent in the seasonally heavier Q3, and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. The most pessimistic target, $406.00, is roughly what ELV is worth if this bites instead.

Read the full bull and bear case on ELV, including what would have to change to break either one. Walnut is not an investment adviser.

Has Elevance Health, Inc. (ELV) split its stock?

No. Elevance Health, Inc. (ELV) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Elevance Health, Inc. (ELV) valued?

Market cap, P/E and dividend yield at today's price are in the ELV key stats above. The business figures below come from Elevance Health, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$202 billion
  • Q3 2026 revenue: ~$50.4 billion; adjusted EPS $6.99 vs ~$4.69 est.
  • Net income (TTM): ~$5.1 billion (GAAP EPS ~$23.55)
  • FY2026 adjusted EPS: guidance at least ~$29; consensus ~$29.14
  • Operating / net margin: ~4.0% / ~2.5%

As of November 2026: Elevance trades at a modest multiple for a company of its size, about 13.4x forward earnings after the November pullback. Q3 2026 was the third straight quarter of large beats (adjusted EPS $6.99 vs ~$4.69, after $7.45 vs ~$6.21 in Q2 and $12.58 vs ~$10.81 in Q1), and the average analyst target is about $482 across 21 analysts, yet the stock fell back from its mid-November high on Medicare Advantage policy news. These figures are approximate and as of November 20, 2026.

What themes does Elevance Health, Inc. (ELV) fit?

These are the investment theses ELV naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Elevance Health, Inc. (ELV)?

Diversified national health insurers

UnitedHealth Group, CVS Health (Aetna), Cigna, and Humana are the peers most directly comparable, each combining insurance with pharmacy or care-services arms. They compete with Elevance for commercial, Medicare Advantage, and Medicaid members and set the benchmark for medical cost management and margins.

Managed Medicaid specialists

Centene and Molina Healthcare focus heavily on government Medicaid and marketplace plans, overlapping with Elevance's large government book. They are useful read-throughs on Medicaid rate adequacy and cost trend, the same pressures Elevance has flagged for 2026.

Pharmacy benefit and care services

Elevance's Carelon and CarelonRx compete with pharmacy benefit managers and care-services players such as CVS Caremark, Cigna's Evernorth, and UnitedHealth's Optum. This is the higher-growth, services-oriented battleground beyond traditional insurance underwriting.

What stocks are similar to Elevance Health, Inc. (ELV)?

Other names that sit close to ELV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Elevance Health, Inc. (ELV)

There are three common ways to get ELV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ELV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ELV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Elevance Health, Inc. (ELV)

Elevance is a scaled, low-multiple health insurer whose story hinges on managing medical cost trend across its Health Benefits and Carelon segments rather than on rapid growth. Three straight large beats lifted 2026 guidance to at least $29 of adjusted EPS, but at about 13x forward earnings the stock shows how much policy risk in Medicare Advantage and Medicaid still weighs on the group.

More on Elevance Health, Inc. (ELV)

Whether ELV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ELV a buy or a sell?, and where the stock could go from here in the ELV stock forecast.

For income investors, whether ELV pays a dividend and how the payout looks is covered in does ELV pay a dividend? And to weigh ELV against a peer, read the full side-by-side comparisons: ELV vs ABBV and ELV vs ABT.

Wondering how ELV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Elevance Health, Inc.

Ask Walnut's AI anything about ELV and see how it fits what you own.

FAQ

What is ELV?

+

ELV is the NYSE ticker for Elevance Health, a large US health insurer and healthcare services company formerly known as Anthem. It operates Blue Cross Blue Shield plans across 14 states and covered roughly 44.9 million medical members as of Q3 2026.

Why did Anthem change its name to Elevance Health?

+

Anthem rebranded to Elevance Health in 2022 to reflect its broader ambition beyond traditional health insurance, including its Carelon health services and pharmacy businesses. The stock ticker changed from ANTM to ELV as part of that transition.

How does Elevance Health make money?

+

Elevance earns premiums from members across commercial, Medicare Advantage, Medicaid, and ACA marketplace plans in its Health Benefits segment. Its Carelon segment adds revenue from pharmacy benefits (CarelonRx) and risk-based care services, a faster-growing, services-oriented part of the business.

What are Elevance's main business segments?

+

The two core segments are Health Benefits, which sold about $167.1 billion of operating revenue in 2025, and Carelon, which grew about 33 percent to roughly $71.7 billion. Health Benefits is the insurance book, while Carelon houses pharmacy and care services.

Is Elevance Health considered a value stock?

+

It is often viewed that way because it trades at a modest earnings multiple, about 13.4 times forward estimates and about 17 times trailing GAAP earnings as of November 2026, below the broad market even after a roughly 14% year-to-date gain. That multiple reflects investor caution about medical cost inflation and government-program policy more than any doubt about the company's scale.

What is the medical loss ratio and why does it matter for ELV?

+

The medical loss ratio (benefit expense ratio) is the share of premiums paid out as medical claims, running near 86.8 percent in Q1 2026 and 90.6 percent in Q3 2026, an improvement of 70 basis points from a year earlier. Because insurance margins are thin, even a few points of increase can meaningfully reduce Elevance's earnings, so investors watch it closely.

What are the biggest risks for Elevance Health?

+

Key risks include rising medical cost trend (especially in Medicaid), heavy exposure to government-set rates for Medicaid and Medicare Advantage, regulatory and political pressure on insurer profits, and integration risk from acquisitions. Thin insurance margins amplify the impact of any adverse cost surprise.

How can I invest in ELV?

+

ELV trades on the NYSE and can be bought through any standard brokerage account, and it is also held within many healthcare and S&P 500 index funds. Walnut is not an investment adviser, so treat this as descriptive information and do your own research before making any decision.

How did Elevance do in its latest quarter?

+

In Q3 2026, reported October 21, Elevance posted operating revenue of about $50.4 billion, up 0.7% year over year, and GAAP net income of about $1.36 billion. Adjusted EPS of $6.99 beat the roughly $4.69 consensus, the third large beat of 2026. The benefit expense ratio improved to 90.6%, membership dipped to about 44.9 million, and 2026 adjusted EPS guidance rose to at least $29. Q4 results are expected around January 28, 2027.

How has ELV stock performed in 2026?

+

As of November 20, 2026, ELV closed near $404.66, up about 14% year to date and about 29% over one year, within a 52-week range of roughly $275 to $451. It reached a 52-week closing high near $446 on November 16, then fell 7.6% on November 18 with the managed care group. The 21 analysts covering it carry an average target near $482. Walnut is not an investment adviser and this is not a recommendation.

Why did Elevance stock fall in November 2026?

+

On November 18, 2026 ELV fell 7.6% with no company-specific news. Managed care stocks dropped together over a federal proposal that could let regulators recover Medicare Advantage overpayments dating back to 2018; Humana fell 13.0% and UnitedHealth 10.2% the same day. Elevance sells Medicare Advantage plans and expects only about a 2% margin on them in 2026, below its 3% to 5% long-term target.

Guides that feature ELV

ELV is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Elevance Health, Inc.'s investor relations page or your broker before making investment decisions.